The Role of N Terminal Pro-BNP in Assessing Severity of Coronary Artery Disease: A Prospective Study

Siddharth Raut, Chandan Saurav Mohapatra, Abdul Wasy, Nooruddin Owaisi, Aleem Ahmed Khan

1 Department of Cardiology, Owaisi Hospital and research centre, Hyderabad, Telangana, India
2 Department of Cardiology, Fortis Hospital, Karnataka, Bangalore, India
3 Department of Pathology, Owaisi Hospital and research centre, Hyderabad, Telangana, India
4 Deccan College of Medical Sciences, Hyderabad, Telangana, India
5 Centre laboratory for Stem cell research and translational Medicine, DCMS, Hyderabad, India

Corresponding Author: Aleem Ahmed Khan, Centre Laboratory for Stem Cell Research and Translational Medicine, Deccan College of Medical Sciences, Hyderabad, Telangana, India. Email: aleem_a_khan@rediffmail.com

Citation: Aleem Ahmed Khan et al. (2017), The Role of N Terminal Pro-BNP in Assessing Severity of Coronary Artery Disease: A Prospective Study. Int J Card & Hear Heal. 1:3, 40-46. DOI: 10.25141/2575-8160-2017-3.0043

Copyright: ©2017 Aleem Ahmed Khan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract:
BNP is a peptide consisting of 2 amino acids produced by the myocytes as a prohormone. It is released as a response to ventricular dilatation and pressure overload in its active form after peptidases degradation, into the cardiovascular system. BNP levels are increased after myocardial infarction and high levels are related to increased risk of adverse events. Acute coronary syndromes without ST elevation encompass a wide range of events and have different prognostic values in relation to the type of plaque lesions and diffusion of coronary atherosclerosis. The risk assessment, based on clinical history and examination, ECG changes and markers of myocardial damage, still remains relatively inaccurate. So this study was planned to better assess the role of NT pro BNP in assessing severity of CAD in real world practice in a prospective manner with well defined patient inclusion and exclusion among a spectrum of NSTEMI.

Keywords: CAD, BNP, ST Elevation, NT Pro BNP and Angiographic Lesions

Introduction
Atherosclerosis has venerable history having left traces in arteries of human mummies. It displays heterogeneity in time, being a disease with both chronic and acute manifestations. Despite its indolent time course and prolonged period of clinical inactivity, the dreaded complication of atheroma such as myocardial infarction, unstable angina or stroke typically occurs suddenly. CAD is assuming serious dimension in developing countries. It is expected to be the single most important cause of death in India by the year 2015. There is a considerable increase in prevalence of CHD in urban areas in India during the last decade. Although there is increase in prevalence of CHD in rural areas also, but it is not that steep because life style changes have affected people in urban areas more than in rural areas (1). The pooled estimates from studies carried out in 1990s upto 2002 shows the prevalent rate of CHD in urban area as 6.4 percent and 2.5 percent in rural areas. In urban areas the pooled estimate was 6.1 percent for males and 6.7 percent for females, in rural areas the estimate was 2.1 percent for males and 2.7 percent for females (2). According to medical certification of cause of death data, 25.1 percent of total deaths in urban areas are attributable to diseases of the circulatory system (1). BNP is a peptide consisting of 2 amino acids produced by the myocytes as a prohormone. It is released as a response to ventricular dilatation and pressure overload in its active form after peptidases degradation, into the cardiovascular system (3). BNP levels are increased after myocardial infarction and high levels are related to increased risk of adverse events. Recently it has been demonstrated that BNP and N terminal pro-BNP (NT pro-BNP) also provide predictive information on acute coronary syndrome and they appear related to the severity of CAD in patients affected with ACS (4,5). Acute coronary syndromes without ST elevation encompass a wide range of events and have different prognostic values in relation to the type of plaque lesions and diffusion of coronary atherosclerosis. The risk assessment, based on clinical history and examination, ECG changes and markers of myocardial damage, still remains relatively inaccurate (6). Elevated BNP and NTproBNP concentrations at admission in the...
setting of acute coronary syndrome (ACS) are associated with poor prognosis, including increased mortality, development of congestive heart failure (CHF), and recurrent ischemic events (3,7,8). Several studies in ACS patients demonstrated a strong association between increased NT PRO BNP and poor clinical outcome however the underlying mechanism responsible for this association is unclear: BNP and NTPROBNP could be indicators for multivessel disease, poor TIMI flow as well as markers of coronary disease extension (5,7).

The present study was planned to better assess the role of NT pro-BNP in assessing severity of CAD in real world practice in a prospective manner with well defined patient inclusion and exclusion among a spectrum of NSTEACS. There are very few reports from India on these studies.

Aims & objectives
1. To estimate the serum level of NT-pro-BNP and Troponin at the time of admission within 24 hours in patients with symptoms suggestive of an acute coronary syndrome and ECG showing no ST-segment elevation.
2. To perform coronary angiography and assess Gensini score.
3. To correlate the NT pro-BNP levels with angiographic lesions and extent and severity of coronary artery disease.

Material and Methods
The present study “N -terminal pro- b-naturetic peptide levels predict extent and severity of coronary artery disease in unstable angina and non ST elevation acute coronary syndrome and normal left ventricular function” was undertaken in the Dept. Of Cardiology of S.C.B. Medical College and Hospital, Cuttack during the period of September 2013 to September 2014.

Selection of Cases
In the present study 72 patients with history of chest pain and other symptoms suggestive of an acute coronary syndrome admitted to the Department Cardiology, S.C.B. Medical College, Cuttack were taken as subjects.

The diagnosis of NSTEMI was made when a patient with the clinical features of UA develops evidence of myocardial necrosis, as reflected by Troponin I >0.06 ng/ml and Troponin T > 14 pg/ml. ECG findings suggestive of UA / NSTEMI (i.e. ECG was considered abnormal) when with the above clinical findings ECG shows ST depression > 0.05 mV, T wave inversion > 0.3mV.

Exclusion Criteria
Patients with past H/o Myocardial infarction, ST elevation on admission, evolution of ECG showing new LBBB or pathological Q WAVES, UA/NSTEACS with LV dysfunction, age more than 80 years, acute or chronic heart failure, Cardiomyopathy, Systolic dysfunction with EF <50%. Patients with Renal, Liver, neoplastic and inflammatory and infectious disease were excluded.

Examination during admission included medical history, clinical examination, routine blood chemistry, Chest X-Ray, ECG, Echocardiography, coronary angiography, Troponin-I/T and NT-proBNP.

NT-pro BNP Analysis
NT-proBNP concentration was measured by Enzyme-linked fluorescent Assay (VIDAS Automated quantitative test).

Troponin – I
Troponin-I concentration was measured by Enzyme-linked fluorescent Assay (VIDAS Automated Quantitative Test). The analyte range was 0.01 to 30 g/L.

Echocardiography
In our study all patients were subjected to M-mode as well as Colour Doppler echocardiography. It was performed with the use of a wide angle rotatory mechanical sector scanner with 3.5 mHz transducer tall tracing for LV dimensions recorded at the level of tips of mitral valve.

The wall motion for each segment was assessed visually in each view and was recorded as – Normal, Akinetic, Hypokinetic, dyskinetic.

Coronary Angiography
Coronary angiography was performed using Judkins catheter following a standard technique. The Gensini scoring system (9) was utilized in the evaluation of CAD severity.

Statistical Analysis
All results for continuous variables were expressed as means ± SD (standard deviation). However, since the distribution of NT-proBNP was skewed, therefore median values were also considered. Difference between mean values was evaluated with unpaired t-test. To compare the patient characteristics defined by the groups with low and high levels of NT-proBNP, we used the Fishers exact test. Correlation coefficients reported between continuous variables were based on Pearson correlation coefficient. A p value <0.05 was considered statistically significant. The data analyses were performed using the SPSSS system 16.0 (Statistical Package for the Social Sciences, Chicago) and GraphPad Instat 3.

Results
In the present study, out of 72 cases of UA / NSTEMI, 43 (59.7%) were males and 29 (40.3%) were females. Majority of male cases was in the age group of 50–69 yrs and majority of females were also seen in the same group (Table 1). Among the two groups of ACS patients selected from the study, largest group was NSTEMI consisting of 56 (77.7%) cases. In the UA group there were 16 (22.3%) cases. Mean NT – proBNP values were higher in cases of NSTEMI compared to cases of UA. The mean NT-proBNP level in NSTEMI was 633 pg/ml and in UA was 381.4 pg/ml (Table 2). There was a significant difference in patients with abnormal ECG (n=52) having higher NT-proBNP levels (832.24 pg/ml) as compared to that of normal ECG (n=16) and levels of 111.67 pg/ml.

Mean NT pro BNP levels were higher in NSTEACS group than in UA Patients and the association was statistically significant (p=0.03) (Table 3). Among the various risk factors present in the cases, it was observed that <2 risk factors were seen in majority (41 cases, 56.9%) and > 2 risk factors were seen in 42.1% of cases. The NT-proBNP levels in patients (n=31) having more than 2 risk factors was higher (931 pg/ml) as compared to the patients (n=41) having less than 2 risk factors (NT-proBNP levels 301.4 pg/ml) which was statistically significant (P=0.12). The patients who had NT-proBNP level more than 258 pg/ml were older, of female gender, had hypertension, smoking history, positive Trop-T/I level. But the difference was not statistically significant (Table 4). Out of
72 cases that underwent Angiography, majority (38 cases, 52.7%) had SVG and 18 cases (25%) had DVD followed by TVE in 16 cases (22.2%) (Table 5). The LAD was the most common artery to be involved in 50 cases (69.4%). The LCX was the next most common artery to be involved in 37 (51.3%) cases. It was followed by RCA artery which was involved in 35 (48.64%) cases (Table 6). Both NT-proBNP and Gensini score were higher in TVE group as compared to DVD and SVG group and the association was statistically significant with p value of 0.022 and 0.014 respectively (Table 7). Patients having NT-proBNP level > 258 pg/ml had more incidences of TVE and also higher Gensini score. This observed difference was statistically significant (Table 8).

**Discussion**

In the present study, 72 cases of Unstable Angina (UA)/Non ST Elevation Myocardial Infarction (NSTEMI) were taken. The cases were divided into 3 age groups: <50 yrs, 50 – 69 yrs and 70 – 79 yrs (Table -1). Maximum number of cases 48(65.2%) were in the 50-69 year age group. 14 cases (19.44%) were in the age group <50 yrs while 10 cases (13.8%) were in the age group of 70-79 years. The youngest case recorded was a male aged 34 yrs. The median age of cases in the group where NT-proBNP ≤ 258 pg/ml was 54 yrs, while in the group where NT-proBNP > 258 pg/ml the median age of cases was 68 yrs. Thus, higher baseline levels of NT-proBNP was directly associated with age i.e. patients with NT-proBNP > 258 pg/ml were older (median age 68 yrs).These finding were consistent with earlier studies by Sadanandan S. et al, Morrow DA et al and Bassan R et al, who also reported that higher level of BNP was seen in older patients (10,11,12).Out of 72 cases NSTEACS was seen in 56 (77.7%) of cases and UA was seen in 16(22.3%) of cases. Both UA/NSTEACS were seen predominantly in males. The mean value of NT-proBNP in males was 547.96 pg/ml whereas in females it was 433.3 pg/ml. The overall mean serum NT-proBNP level was significantly higher in NSTEACS patients compared to UA (Table 2). This again was consistent with studies by Palazzuoli et al (13).

Patients having abnormal ECG had a significant higher NT-proBNP levels compared to those having normal ECG. This finding was consistent with earlier studies by Bassan R et al Lindahl et al and Heeschen. (12, 14-15).

Diabetes, hypertension smoking and dyslipedemia were seen more in NSTEACS group than in UA patients but difference was not statistically significant (Table-3). It is consistent with studies by Palazzuoli et al (13). It was observed that < 2 risk factors were seen in majority (41 cases, 56.9%) and > 2 risk factors were seen in 42.1% of cases. The NT-proBNP levels in patients having more than 2 risk factors was higher than the patients having less than 2 risk factors which was statistically significant(P=0.12).It was consistent with earlier studies by Goyal et al(16).

The median value of NT-proBNP in the case group was 258.0 pg/ml (Table 4). The median value obtained in our study (258.0 pg/ml) was consistent with study by Heeschen C. et al where the median was 250pg/ml (15). The median NT-proBNP level in the Galvani M. et al & Estrada JLN et al studies were 354 pg/ml and 278.7 pg/ml respectively (17,18). The 25th, 50th, 75th percentile values of NT-proBNP were 105.0, 258.0 and 1149.5 pg/ml respectively in our study. This was similar to findings of Jernberg et al where it was 112.0, 400.0 and 1654.0 pg/ml (19) and Estrada et al (18) where it was 109.8, 278.7 & 758.5 pg/ml respectively. Out of a total number of 29 female patients, 17(58.67%) had NT-proBNP levels >258.0 pg/ml, while only on 20 males (46.11%) out of a total 43 males had supramedian NT-proBNP levels. Thus, higher NT-proBNP levels were seen in the female gender. Similar observation was seen by James SK et al in the GUSTO-IV substudy (21).

It was clear that though NT-proBNP level was higher among hypertensives, diabetics and smokers, still, the association was not significant. Similar observations were noted by Sadanandan et al (10).

The patients who had NT-proBNP level more than 258 pg/ml were older, of female gender, had hypertension, had smoking history , positive Trop-T/I level . But the difference were not statistically significant , similar observation was seen in the study by Goyal et al. Of the 72 cases, undergone angiography (Table 5). 38(52.7%), 18(25%) and 16 (22.22%) cases had single, double and triple vessel disease respectively. This was consistent with study by Estrada JLN et al (18) who also reported SVD was more common (in 32%) cases than DVD (in 26% cases) and TVE (in 25% cases). It was seen that predominant artery involved was LAD (69%) cases followed by LCX (51%) cases, followed by RCA in 48% cases (Table 6 ).This is consistent with earlier studies by Estrada JLN et al and Hong SN et al (18,22).

From Table 7, it was observed that patients with double / triple vessel disease had higher NT-proBNP levels while patients with single vessel disease had significantly lower NT-proBNP levels. Similar observations were made by Sadanandan S. et al,Estrada JLN et al, and Hong SN et al in their studies (10,18,22). The mean NT pro BNP levels and Gensini scores were higher in TVE cases as compared to DVD and SVD cases. This marked difference was statistically significant. This observation was also seen by studies by Palazzuoli et al and Goyal et al (13,16).

It was observed that patients having higher median NT-proBNP level (> 258 pg/ml) had more incidence of TVE and also higher gensini score as compared to lower median BNP levels (Table 8). This observed difference was statistically significant which was similar to the observations in a study by Goyal et al (16).

Elevated NT-proBNP levels had a close relation with the number of vessels involved (23).Even in patients with normal LV function, the level of NT-proBNP maintains the same relation with the extension of CAD (24). Thus a mechanism other than LV dysfunction might be responsible for the adverse outcome in patients with NSTEACS and high levels of NT-proBNP . Toth et al (25) have found evidence that tissue hypoxia alone triggers release of BNP in absence of LV dysfunction. These results were confirmed by a recent physiological study showing that ventricular BNP gene expression is up-regulated by myocardial hypoxia resulting in augmented plasma concentrations of BNP and NT-proBNP (26). The association of elevations of BNP with a greater severity and extent of ischemia may explain, at least in part, the adverse clinical outcomes of such elevation.
Many studies have shown that the elevation of BNP levels, as well as NT-proBNP levels, obtained after the acute phase in patients with a broad range of ACS independently predicts mortality. However, in most of the reports, authors did not distinguish between subjects with low ejection fraction and LV enlargement (27). Because of its release in response to increased ventricular chamber pressure or wall tension, in ACS patients with decreased LV ejection fraction, elevated BNP levels reflect a high degree of myocardial dysfunction, with a higher risk of death and congestive heart failure.

The main finding of this study is that BNP levels are related to the severity of coronary atherosclerosis. Patients with multi-vessel disease showed higher BNP levels than subjects with only one or two vessel involvement. This trend was confirmed independently of the diagnosis of USA or NSTEACS groups. Elevation of BNP levels appears strictly related to coronary artery disease. Our results are in accordance with those of Sadanandan et al showing a correlation between TIMI flow, thigh of culprit stenosis and BNP levels (10).

However, with respect to the cited study, our sample was characterized by the absence of left ventricular dysfunction and enlargement which are the main factors responsible for BNP increase.

Again, we demonstrated that NT PRO BNP threshold of 258 pg/ml appears able to predict the extension of coronary disease independently from LV systolic dysfunction and enlargement. The same value has been previously recognized as cutoff for mortality and risk for adverse events in patients with ACS. This study result is also in accordance with study by Goyal et al (16) Importantly our study showed that high NT pro BNP (>258 pg/ml) is a strong predictor of Triple vessel disease irrespective diagnosis of UA/NSTEACS.

The exact mechanisms of natriuretic peptides rise in coronary disease are not completely understood. Ischemia may constitute an independent stimulus for BNP release towards a transient decrease of systolic function and compliance, reflecting not only the impairment in left ventricular function, but also the severity of the ischemic insult (28).

Alternatively, BNP secretion may be due to the augmented regional wall stretch which occurs during ischemic attacks even in the absence of pump dysfunction inducing the neurohormonal activation.

The detection of BNP gene expression in ischemic and infarcted regions together with BNP receptor recruitment in coronary plaques could explain a novel mechanism of BNP induction (29,30).

The strong correlation between the Gensini Score and BNP levels extend previous findings demonstrating that a further stimulus for BNP increase could be the severity and diffusion of coronary plaques that, consistent with this observation, lead to a worsening of the ischemic myocardial area (29). All together these data could explain the mechanisms linking BNP to an adverse outcome in CAD: it represents a marker of coronary disease severity and is related to the presence of plaques diffusion and narrowing. For the above mentioned reasons NT pro BNP may considered as an indicator of regional ischemia and as a predictor for adverse events in patients UA/NSTEACS.

The present study suffers from several limitations, the major one is the small sample size. However our sample was carefully defined and selected on the basis of echocardiographic and clinical criteria. Age and sex could have influenced the findings even if the population studied had similar demographic characteristics in all groups. Our study did not compare BNP levels to other biomarkers of myocardial injury such as Troponin, high sensitive CRP or cytokine levels. Conclusion BNP represents a biomarker for left ventricular dysfunction and enlargement as well as for myocardial ischemia. It appears able to gives additional prognostic information to existing traditional biomarkers (i.e. troponin and C-reactive protein).

BNP is a candidate for entry into the setting of principal risk scores. Our findings indicate that the level of BNP may reflect the extent or severity of ischemic insult even when irreversible injury and systolic dysfunction have not occurred.

High NT pro BNP levels significantly associated not only with multivessel coronary artery disease but also adverse cardiovascular risk and outcomes.

Future trials should be designed to evaluate targeted therapies based on elevations in the levels of one or more markers occurring in conjunction with the pathophysiologic mechanisms of necrosis, inflammation, or ischemia causing myocardial stretch. Such trials will provide further insights into the interaction between troponins, inflammatory markers, and natriuretic peptides in the pathogenesis and dynamic risk assessment of NSTEACS/UA patients.

Table 1: Age & Sex Distribution in Cases

| Age Groups (in yrs) | Case (n=72) |
|---------------------|-------------|
|                     | Male (n = 43) | Female (n = 29) |
| <50                 | 9            | 6             |
| 50-69               | 26           | 21            |
| 70-79               | 8            | 2             |

International Journal of Cardiology and Heart Health Volume 1 Issue 3, October 2017
Table 2: Incidence of Non-ST Elevation Myocardial Infarction (NSTEMI)/Unstable Angina (UA) cases and their Mean NT-ProBNP levels

| Types  | Males | | Females | | Mean NT-proBNP level (pg/ml) |
|--------|-------|---|-------|---|------------------|
|        | Number | NT-proBNP level (pg/ml) | Number | NT-proBNP level (pg/ml) | |
| NSTEMI | 34 (79%) | 687.6 | 22 (75%) | 579.4 | 633 |
| UA     | 9 (21%) | 408.4 | 7 (25%) | 287.7 | 381.4 |

Table 3: Clinical characteristics and risk factors

| Risk factors | UA (n=16) | NSTEMI/ACS (n=56) | p value |
|--------------|-----------|-------------------|---------|
| Male         | 9         | 34                | 0.9     |
| Diabetes     | 4         | 16                | 0.44    |
| Hypertension | 6         | 24                | 0.29    |
| Smoking      | 4         | 22                | 0.07    |
| Dyslipidemia | 6         | 16                | 0.22    |
| NT-ProBNP (mean ±SD) | 277±191 | 669±540 | 0.03 |

Table 4: Baseline Characteristics (Taking median into account)

| Serum NT-proBNP Level (pg/ml) | p value |
|-------------------------------|---------|
| Baseline Character | ≤ 258 | > 258 |
| Age, median (yrs) | 54 | 68 | 0.332 |
| Males (n = 43) | 23 (53.16) | 20 (46.84) | 0.156 |
| Females (n = 29) | 12 (43.33) | 17 (56.67) | 0.075 |
| Diabetes Mellitus (n = 24) | 14 (62.50) | 10 (37.50) | 0.342 |
| Hypertension (n = 37) | 15 (42.60) | 22 (57.40) | 0.45 |
| Smoking (n = 24) | 10 (40) | 14 (60) | 0.14 |
| Dyslipidemia (n = 25) | 13 (52%) | 12 (48%) | 0.32 |
| Trop-1 (n = 45) | | |
| (<0.11 pg/L) Trop-T (>1-4pg/ml) | 14 (32.80) | 29 (67.20) | 0.0065 |

The 25th, 50th, 75th percentile values of NT-proBNP were 105.0, 258.0 and 1149.5 pg/ml respectively. Taking the median value (258 pg/ml) the baseline characteristics were compared.
Table 5: Coronary angiography profile - incidence of single vessel disease / Double vessel disease / Triple vessel disease in coronary angiography in case group

| Coronary artery involved          | Cases (n=72) | Percentage |
|-----------------------------------|--------------|------------|
| **SVD (Single Vessel Disease)**   | 38           | 52.7%      |
| LAD                               | 20           |            |
| LCX                               | 8            |            |
| RCA                               | 10           |            |
| **DVD (Double Vessel Disease)**   | 18           | 25%        |
| LAD + LCX                         | 9            |            |
| LAD + RCA                         | 5            |            |
| LCX + RCA                         | 2            |            |
| **TVD (Triple Vessel Disease)**   | 16           | 22.2%      |

Table 6: Prevalence of vessel involvement seen in angiography

| Vessel involved | No. of cases | Percentage |
|-----------------|--------------|------------|
| LAD             | 50 (69.4%)   |            |
| LCX             | 37 (51.3%)   |            |
| RCA             | 35 (48.6%)   |            |

Table 7: NT ProBNP and extent of CAD

| No. of cases | SVD | DVD | TVD | p value |
|--------------|-----|-----|-----|---------|
|              | 38  | 16  | 18  | 0.022   |
| NT ProBNP (pg/ml) | 331.2±270.8 | 775.2±439.3 | 1164.4±596.1 | 0.014 |
| Gensini score | 16.8±7.8 | 38.6±9.4 | 62.2±20.6 | 0.014 |

Table 8: NT-ProBNP (median) and association with severity of CAD

| Baseline Character | Serum NT proBNP level (pg/ml) | p value |
|-------------------|--------------------------------|---------|
|                   | ≤ 258                          | > 258   |
| TVD (n=16)        | 3(18.75%)                      | 13(81.25%) | 0.003  |
| G. Score          | 12.4±15.8                      | 42.6±27.9 | 0.012  |

References
1. K. Park. Coronary Heart Disease. Park’s Text book of Preventive and Social Medicine. 20th Edn. 2009; 6: 317 – 323.
2. ICMR (2004), Assessment of Burden of Non-communicable disease, Final Report.
3. Bassan R. Alfredo Potsch, Alan Maisel et al: BNP; a novel early blood marker of AMI in patients with chest pain and no ST-segment elevation, European Heart Journal. 2005, 26: 234-240.

International Journal of Cardiology and Heart Health

Volume 1 Issue 3, October 2017
4. Jernberg T, Stridsberg M, Venge P et al: N-terminal proBNP on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002; 40: 343-3445.
5. Morrow DA, De Lemos JA, Blazing MA et al: Prognostic value of serial B-type natriuretic peptide testing during follow up of patients with unstable coronary artery disease, JAMA 2005; 294: 2866-2871.
6. Weber M, Bazzino O, Navarro JL et al: N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndrome and normal troponin T values upon admission, J Am Coll Cardiol 2008; 51: 1188-95.
7. James SK, Lindahl B, Siegbahn A et al: N-terminal pro-BNP and other markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: A Global Utilization of Strategies to open to open occluded arteries (GUSTO) – IV substudy. Circulation, 2003; 108: 275-281.
8. Braunwald E, Morrow D, De Lemos JA et al: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001; 345: 1014-21.
9. Gensini GG: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606
10. Sadanandan S, Christopher P, Kasi Chekuri, Cannon et al. Association of Elevated B-Type Natriuretic Peptide Levels With Angiographic Findings Among Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2004;44;564-568.
11. Morrow DA, De Lemos JA, Blazing MA et al: Prognostic value of serial B-type natriuretic peptide testing during follow up of patients with unstable coronary artery disease, JAMA 2005; 294: 2866-2871.
12. Bassan R, Alfredo Potsch, Alan Maisel et al. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. European Heart Journal 2005 26(3):234-240.
13. Alberto Palazzuoli, Maisel A, Caputo M et al. B-type natriuretic peptide levels predict extent and severity of coronary disease in non-ST elevation coronary syndromes and normal left ventricular systolic function. Regul Pept. 2011;167:129-133
14. James SK, Lindahl B, Siegbahn A et al: N-terminal pro-BNP and other markers for the se Palazzuoli parate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: A Global Utilization of Strategies to open to open occluded arteries (GUSTO) – IV substudy. Circulation, 2003; 108: 275-281.
15. Heeschen C, Hamm CW, Brueummer J et al, for the Chimere c7E3 Anti-Platelet Therapy in Unstable Angina. REfractory to standard treatment trial (CAPTURE) Investigators: Predictive value of C-reactive protein and troponin T in patients with Unstable Angina: A comparative analysis. J. Am Coll Cardiol 35: 1535 – 42, 2000.
16. Goyal b, S.M. Sharma, and Mohit Walia et al; B-type natriuretic peptide levels predict extent and severity of coronary disease in non-ST elevation coronary syndromes and normal left ventricular function. Indian heart jour: 2014;66:183-187
17. Galvani M Ottani, F., Oltrona, L. et al, N-terminal proBNP on admission has prognostic value across the whole spectrum of acute coronary syndromes, circulation, 2004; 110 : 128-134.
18. Estrada JLN, Fernando Rubinstein, Maria Cecilia Bahit et al. NT-probrain natriuretic peptide predicts complexity and severity of the coronary lesions in patients with non-ST-elevation acute coronary syndromes. Am Heart J 2006;151:1093.e1-1093.e7.
19. Jernberg T, Stridsberg M, Venge P, et al. N-terminal pro brain natriuretipeptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002; 40:437-445.
20. Jernberg T, Stridsberg M, Venge P, et al. N-terminal pro brain natriuretipeptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002; 40:437-445.
21. James SK, Lindahl B, Siegbahn A et al: N-terminal pro-BNP and other markers for the prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: A Global Utilization of Strategies to open to open occluded arteries (GUSTO) – IV substudy. Circulation, 2003; 108: 275-281.
22. Hong S.N. Nam Sik Yoon, Youngkeun Ahn et al. N-terminal pro-B-type natriuretic Peptide predicts significant coronary artery lesion in the unstable angina patients with normal electrocardiogram, echocardiogram, and cardiac enzymes. Circ J 2005; 69: 1472 – 1476.
23. Ndrepepa G, Braun S, Mehilli J et al. Plasma levels of NT-proBNP in patients with CAD and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. Am J Cardiol 2005;95:553-7.
24. Estrada JLN, Fernando Rubinstein, Maria Cecilia Bahit et al. NT-probrain natriuretic peptide predicts complexity and severity of the coronary lesions in patients with non–ST-elevation acute coronary syndromes. Am Heart J 2006;151:1093.e1-1093.e7.
25. Toth M, Vuorinen KH, Vuolteenaho O, et al. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardi um. Am J Physiol 1994;266:H1572-80.
26. Goetze JP, Christoffersen C, Perko M. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003;17:1105-7.
27. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014–1021.
28. Marumoto K, Hamada M, Hiwada K. Increased secretion of atrial and brain natriuretic peptides during acute myocardial ischemia induced by dynamic eStaub D, Nusbaumer C, Zellweger MJ, et al. Use of B-type natriuretic peptide in the detection of myocardial ischemia. Am Heart J 2006;151:1223–30.
29. Burley DS, Hamid SA, Baxter GF. Cardioprotective action of peptide hormones in myocardial ischemia. Heart Fail Rev 2007;12:279–91.
30. Barbato E, Rubattu S, Bartunek J et al. Human coronary ath erosclerosis modulates cardiac natriuretic peptide release. Atherosclerosis 2009;206(1):258–64.